



DNAtrix Awarded \$10.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Grant to Be Used to Fund Ongoing Clinical Trials for Brain Cancer

February 24, 2014 07:15 AM Eastern Standard Time

HOUSTON--([BUSINESS WIRE](#))--DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that it has been awarded a product development grant for \$10.8 million to fund the company's clinical-stage program in glioblastoma—the most aggressive type of brain cancer. The grant from the Cancer Prevention and Research Institute of Texas (CPRIT) is entitled "Clinical development and commercialization of oncolytic adenovirus for treating malignant glioma."

"We appreciate the support from such a reputable organization as CPRIT, as it offers additional validation of our cancer program and the clinical benefits that we continue to observe in our clinical trials including long-term survival and tumor destruction."

The grant awarded to DNAtrix will be used to drive the clinical development of DNX-2401, the lead product candidate that is currently undergoing a Phase Ib trial in combination with temozolomide for recurrent glioblastoma. DNX-2401 uses a genetically modified adenovirus that kills tumor cells selectively. In an earlier Phase I study in recurrent glioblastoma, DNX-2401 demonstrated an excellent safety profile and promising efficacy results.

The CPRIT grants support oncology-focused research and development conducted by Texas-based companies and relocation of existing oncology-focused companies to Texas. These grants cover a range of product development sectors including therapeutics, devices and drug development. After undergoing CPRIT's review process, the grants were recommended by their respective program review councils and approved by the Oversight Committee.

"We are thrilled to receive this generous grant from the Cancer Prevention and Research Institute of Texas, as these funds will accelerate DNAtrix's efforts to pursue the clinical development of our lead oncolytic virus product for glioblastoma," said Dr. Frank Tufaro, Chief Executive Officer of DNAtrix. "We appreciate the support from such a reputable organization as CPRIT, as it offers additional validation of our cancer program and the clinical benefits that we continue to observe in our clinical trials including long-term survival and tumor destruction."

About CPRIT

Beginning operations in 2009, CPRIT provides funding for scientific research, product development and prevention programs. Learn more at www.cprit.state.tx.us.

About DNatrix Inc.

As a clinical-stage company developing modified oncolytic viruses for the treatment of the most aggressive forms of cancer, DNatrix is a privately held company headquartered in Houston, Texas. For more information, please visit the company website at <http://www.dnatrix.com>.

Contacts

DNatrix Inc.
Michelle Chen, 650-690-6470
Chief Business Officer
mchen@dnatrix.com